Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Classical hematology 1

Conditions

Colorectal Neoplasms 187Carcinoma, Non-Small-Cell Lung 85Breast Neoplasms 66Neoplasms 62Ovarian Neoplasms 59Glioblastoma 40Carcinoma, Hepatocellular 36Neoplasm Metastasis 32Colonic Neoplasms 27Carcinoma, Renal Cell 24Fallopian Tube Neoplasms 23Uterine Cervical Neoplasms 21Rectal Neoplasms 17Pancreatic Neoplasms 17Lung Neoplasms 17Stomach Neoplasms 15Liver Neoplasms 15Brain Neoplasms 14Non-Squamous Non-Small Cell Lung Cancer 13Endometrial Neoplasms 11Recurrence 10Glioma 10Carcinoma, Ovarian Epithelial 10Triple Negative Breast Neoplasms 9Melanoma 9Gastrointestinal Neoplasms 9Advanced Solid Tumors 9Solid Cancers 7Peritoneal Neoplasms 7Parkinson Disease 4, Autosomal Dominant Lewy Body 7

Interventions

pegfilgrastim 3Vancomycin 2trametinib 1dabrafenib 1ceftobiprole medocaril 1Teicoplanin 1Mannose-Binding Lectin 1Itraconazole 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Doxorubicin 1Docetaxel 1Cyclophosphamide 1Cefepime 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Fever × Bevacizumab × Clear all
NCT00911170 2017-12-29

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

Amgen

Phase 3 Completed
847 enrolled 21 charts
Classical hematologyGastrointestinal

Colonic Neoplasms, Fever, Neoplasms, Neutropenia, Rectal Neoplasms, Colorectal Neoplasms, Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡